Septic Shock clinical trials at UCSF

2 research studies open to eligible people

Septic shock is a serious condition where the body’s response to infection causes organ failure. UCSF is studying how a treatment called Polymyxin B Hemoperfusion might help people with septic shock. Another trial is testing if hydrocortisone can safely support children with this condition.

Showing trials for

  • Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study

    open to eligible people ages 18 years and up

    Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock

    San Francisco, California and other locations

  • Stress Hydrocortisone in Pediatric Septic Shock

    open to eligible people ages 1 month to 17 years

    SHIPSS is a multi-institutional, prospective, controlled, randomized, double-blinded interventional trial that will examine the potential benefits and risks of adjunctive hydrocortisone prescribed for children with fluid and vasoactive-inotropic refractory septic shock. It is hypothesized that adjunctive hydrocortisone will significantly reduce the incidence of new and progressive organ dysfunction (primary outcome) and proportion of children with poor outcomes, defined as death or severely impaired health-related quality of life (HRQL) (secondary outcome), as assessed at 28 days following study enrollment (randomization).

    Oakland, California and other locations

Our lead scientists for Septic Shock research studies include .

Last updated: